Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News AVEO Oncology begins Phase 1b/2 ficlatuzumab trial in elderly AML patients via Blood Cancer United collaboration AVEO Oncology has begun a Beat AML trial for ficlatuzumab in elderly AML patients. See how this could reshape front-line cancer care for high-risk groups. bySrinathJanuary 16, 2026